Ripasudil

Ripasudil (also known as K-115) is a drug used for the treatment of glaucoma and ocular hypertension. It is a ROCK inhibitor, specifically inhibiting Rho-associated protein kinase (ROCK), which is involved in the regulation of the tone of smooth muscle and intraocular pressure.

Mechanism of Action

Ripasudil works by inhibiting the Rho-associated protein kinase (ROCK), which is involved in the regulation of the tone of smooth muscle and intraocular pressure. This inhibition results in the relaxation of the Trabecular meshwork, allowing for increased outflow of aqueous humor and a subsequent decrease in intraocular pressure.

Uses

Ripasudil is primarily used for the treatment of glaucoma and ocular hypertension. It is often used when other treatments have failed or are not suitable. It can be used alone or in combination with other glaucoma medications.

Side Effects

Common side effects of Ripasudil include conjunctival hyperemia, corneal verticillata, and instillation site pain or discomfort. Less common side effects can include blepharitis, conjunctival hemorrhage, and eye pruritus.

History

Ripasudil was approved for medical use in Japan in September 2014. It is marketed under the brand name Glanatec.

See Also

• Rho kinase
• Glaucoma
• Ocular hypertension

Ripasudil Resources
Latest articles Most recent articles Ongoing trials	Wikipedia